news

Clinical trial of Futura Medical’s MED2002 commences

0
SHARES

Posted: 25 June 2015 |

Futura Medical has received all of the regulatory approvals needed to begin its efficacy trial of erectile dysfunction treatment MED2002…

Futura Medical has received all of the regulatory approvals needed to begin its pivotal efficacy trial of MED2002, the Company’s topical gel for the treatment of erectile dysfunction.

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

med2002

Pre-screening of patients has already commenced.

The design of the trial has been modified to include a larger number of patients, which will increase the statistical robustness of the outcomes from the study.  A total of 192 patients are now expected to take part in the trial, which is taking place in the UK in London.

The primary end point of the trial is the efficacy of MED2002 in male subjects self-diagnosed with erectile dysfunction using the erectile function domain of the International Index of Erectile Function (IIEF). The IIEF is a well validated measure of erectile function and was used for the approval of PDE5 inhibitors, such as Viagra®. Secondary endpoints in the trial will include the speed of onset.

Futura has received interest from potential commercial partners for MED2002

The trial will be of a randomised, placebo-controlled, double blind, home use, crossover design. The increased number of patients means that the study is expected to report in H1 2016, compared with earlier guidance of Q4 2015. Further recruitment sites within the EU have been identified and, pending satisfactory country specific regulatory and ethical approvals, it may be possible to accelerate patient recruitment and thereby achieve an earlier reporting date.

Assuming that this trial is successful, it is expected to be one of two pivotal trials required for the regulatory filing of the product. Futura has received interest from potential commercial partners for MED2002 and the commercialisation strategy, including design of the second pivotal trial, will be decided following the results of the current trial. 

James Barder, Futura’s Chief Executive, commented, “We are delighted that this clinical study of MED2002 has now commenced in the UK. We are using an enhanced trial design which includes an increased number of patients to improve the power of the statistical analysis in this pivotal study.”

Related topics

Related organisations

Share via
Share via